CEBPB and glioma: While C/EBPδ has not previously been associated with drug sensitivity, high expression is known be associated with poor prognosis across glioblastomas [37] and the closely related C/EBPβ is recognized as a synergistic master regulator with STAT3 of the mesenchymal phenotype in aggressive glioma [38].